Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/9420
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAxmedov X., Raximov S.-
dc.date.accessioned2023-11-26T15:44:10Z-
dc.date.available2023-11-26T15:44:10Z-
dc.date.issued2023-
dc.identifier.citationToshkenten_US
dc.identifier.issn2181-7812-
dc.identifier.urihttp://repository.tma.uz/xmlui/handle/1/9420-
dc.description.abstractAnkilozlovchi spondiloartrit (AS) patogenezida ishtirok etadigan sitokin IL-17 darajasi kasallikning faolligi bilan bog‘liq va u anti-TNF-a ga javob bermaydigan AS bemorlarini davolashda asos sifatida ishlatiladi. Ushbu tadqiqotda IL-17 ning ankilozlovchi spondiloartrit kasalligi faollik ko‘rsatkichi C-reaktiv oqsil (ASDAS-CRO) bilan o‘lchanadigan kasallik faolligi bilan bog‘liqligi o‘rganildi. Tadqiqotda korrelyatsiya kuchini ko‘rish uchun Spearman’s korrelyatsiya testi yordamida kasallik faolligi va IL-17 darajasi tahlil qilindi. Qirqta AS ga chalingan bemorlarning o‘rtacha Yoshi 53,58 ± 9,28 yil, tana vazni indeksi 24,36 ± 3,23 kg / m2, ECHT 39,50 ± 18,76 mm / soat, klinik olingan Shober sinamasi13,11 ± 1,27 sm, tranzit testi ± 1,27 sm. O‘rtacha CRO va IL-17 mos ravishda 0,3 (0,10-5,70) mg / dL va 9,30 (7,70- 13,60) pg / dL ni tashkil etdi . ASDAS-CRO tizimiga asoslanib, bemorlar yuqori (62,5%), o‘rtacha (35%) va harakatsizlik (2,5%) toifasiga kiruvchi kasallik faolligini ko‘rsatdi. IL-17 darajasi AS bilan kasallangan bemorlarda kasallik faolligi bilan kuchli bog‘liqdir.en_US
dc.language.isootheren_US
dc.relation.ispartofseriesУДК;616.711-002.72-007.274 -085-
dc.subjectAnkilozlovchi spondiloartrit; IL-17; ASDAS; BASDAI; Shober sinamasien_US
dc.titleAnkilozlovchi spondiloartritda IL-17 ning kasallik kechishidagi axamiyatien_US
dc.typeArticleen_US
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
46. ВЕСТНИК Axmedov X.S Raximov S.SAnkilozlovchi spondiloartritda IL-17 ning kasallik kechishidagi axamiyati696.4 kBUnknownView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.